198 related articles for article (PubMed ID: 31732149)
1. A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol.
Messina JC; Offman E; Carothers JL; Mahmoud RA
Clin Ther; 2019 Nov; 41(11):2343-2356. PubMed ID: 31732149
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.
Vutikullird AB; Gillespie M; Song S; Steinfeld J
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):207-14. PubMed ID: 26624976
[TBL] [Abstract][Full Text] [Related]
3.
Hosseini S; Wei X; Wilkins JV; Fergusson CP; Mohammadi R; Vorona G; Golshahi L
J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):374-385. PubMed ID: 31464547
[No Abstract] [Full Text] [Related]
4. Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study.
Ratner PH; Melchior A; Dunbar SA; Tantry SK; Dorinsky PM
Clin Ther; 2012 Jun; 34(6):1422-31. PubMed ID: 22621776
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.
Nugent C; Yiu G; Song S; Caracta C
J Asthma; 2018 Aug; 55(8):898-906. PubMed ID: 28933971
[TBL] [Abstract][Full Text] [Related]
7. Nasal Deposition of HFA-Beclomethasone, Aqueous Fluticasone Propionate and Aqueous Mometasone Furoate in Allergic Rhinitis Patients.
Leach CL; Kuehl PJ; Chand R; McDonald JD
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):334-40. PubMed ID: 25671692
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
Derendorf H; Munzel U; Petzold U; Maus J; Mascher H; Hermann R; Bousquet J
Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.
Kirjavainen M; Mattila L; Vahteristo M; Korhonen J; Lähelmä S
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):290-297. PubMed ID: 29493402
[TBL] [Abstract][Full Text] [Related]
10. Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers.
Comer GM; Bush MA; Dellon ES; Marino MT
J Clin Pharmacol; 2020 Jun; 60(6):734-743. PubMed ID: 31943257
[TBL] [Abstract][Full Text] [Related]
11. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations.
Daley-Yates PT; Baker RC
Br J Clin Pharmacol; 2001 Jan; 51(1):103-5. PubMed ID: 11167672
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
13. Respiratory Tract Deposition of HFA-Beclomethasone and HFA-Fluticasone in Asthmatic Patients.
Leach CL; Kuehl PJ; Chand R; McDonald JD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):127-33. PubMed ID: 26061801
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems
.
Wayne D; Iverson H; Gillespie M; Hellriegel E; Small C
Int J Clin Pharmacol Ther; 2019 Jan; 57(1):43-54. PubMed ID: 30431426
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
[TBL] [Abstract][Full Text] [Related]
16. A Phase I, Open-label, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability of Intranasal and Oral Varenicline.
Nau J; Wyatt DJ; Rollema H; Crean CS
Clin Ther; 2021 Sep; 43(9):1595-1607. PubMed ID: 34456060
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
Mehta R; Riddell K; Gupta A; Louey MD; Chan RH
Clin Drug Investig; 2015 May; 35(5):319-26. PubMed ID: 25805608
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations.
Patel P; Salapatek AM; Talluri RS; Tantry SK
Allergy Asthma Proc; 2018 May; 39(3):224-231. PubMed ID: 29669667
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.
Brutsche MH; Brutsche IC; Munawar M; Langley SJ; Masterson CM; Daley-Yates PT; Brown R; Custovic A; Woodcock A
Lancet; 2000 Aug; 356(9229):556-61. PubMed ID: 10950233
[TBL] [Abstract][Full Text] [Related]
20. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
